“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A study looking at blood vessel cells in the bloodstreams of women having chemotherapy for ovarian, primary peritoneal or fallopian tube cancer
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
Cancers need a blood supply to help them grow and survive. So growing cancers encourage the growth of new blood vessels. This is called angiogenesis. New drugs (anti angiogenics) are being developed that will block this process. But they don’t work for everyone. At the moment the only way doctors can tell if these drugs are working is by looking at a CT scan after you’ve had treatment. They need to develop other tests that show if anti angiogenics are working earlier than this.
A way to do this may be by looking at damaged blood vessel lining cells that are released into the bloodstream. These lining cells are called endothelial cells, so those in the bloodstream are called circulating endothelial cells (CECs). Researchers have found that increased numbers of CECs in people with cancer may be a sign (biomarker) that new blood vessels are being formed. If the number of CECs drops during treatment, it could show that anti angiogenic treatment is working.
Firstly, researchers would like to measure this when people are having a chemotherapy called paclitaxel. We know that paclitaxel blocks blood vessel growth. They will look at the effect of paclitaxel chemotherapy on the number of CECs. If they can see that paclitaxel reduces the number of CECs, this may also be a way of measuring how well other anti angiogenic drugs are working in future. They will also look for other related
Who can enter
You can enter this study if you
- Have ovarian cancer, primary peritoneal cancer or fallopian tube cancer
- Are due to have paclitaxel or paclitaxel and carboplatin chemotherapy
- Are at least 18 years of age
You cannot enter this study if you
- Have a condition that makes it difficult for you to give blood, for example clotting problems or difficult veins
- Have hepatitis B, hepatitis C or HIV
- Are having, or have just finished treatment with heparin (a blood thinning injection)
- Have a disease affecting your connective tissue, for example lupus or
- Have problems with inflamed blood vessels
- Have sickle cell disease
This study will recruit 30 women into 2 groups. The group you are in depends on the chemotherapy you are having. Some women have paclitaxel every 3 weeks, some have it weekly. These groups simply help separate the results for the researchers. Everyone will give 3 blood samples (up to 2 tablespoons each sample) during the study. These will be
- In the week before you start chemotherapy (2 samples)
- In week 6 of your chemotherapy
When joining the trial, you give permission for the team to store these blood samples to use both now and in future research. You also give the study team permission to collect information from your medical notes including about your cancer, treatment and test results.
The team will regularly check your medical notes to see how you are getting on, for up to 3 years after you finish the study.
Throughout the study you stay under the care of your usual cancer specialist.
The team will try to arrange for you to give your blood samples when you are already at the hospital for your chemotherapy. So you should not have to make any extra visits to take part in this study.
As there are no treatments as part of this study, there are no side effects. You may have a small bruise where you gave your blood samples.
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Gordon Jayson
Experimental Cancer Medicine Centre (ECMC)
The Christie NHS Foundation Trust